Dianthus Therapeutics, Inc. /DE/ 8-K

What Happened
Dianthus Therapeutics announced (via an 8-K filed June 12, 2026) that it posted an updated corporate presentation on its investor relations website on June 11, 2026. The presentation includes an interim responder analysis for the first 40 patients who completed Part A of the Phase 3 CAPTIVATE trial of claseprubart in chronic inflammatory demyelinating polyneuropathy (CIDP). The presentation is filed as Exhibit 99.1 and is incorporated by reference into the 8-K.

Key Details

• The update was posted to the company’s investor relations site on June 11, 2026 and disclosed in an 8-K filed June 12, 2026.
• Interim responder analysis covers the first 40 patients who completed Part A of the Phase 3 CAPTIVATE trial.
• Investigational drug: claseprubart, being evaluated in CIDP (chronic inflammatory demyelinating polyneuropathy).
• The presentation containing the data is attached to the 8-K as Exhibit 99.1.

Why It Matters
Interim responder data from a Phase 3 trial is a material clinical milestone that provides early insight into how the investigational therapy is performing in a larger, pivotal study. Posting the presentation publicly gives investors and analysts direct access to the company’s latest clinical progress on claseprubart and is a tracked near‑term update for the CAPTIVATE program.